Skip to content
All resources

ERR and AMPK research

ATX-304 (O304) and AMPK: What the Research Actually Shows

JH

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What does AMPK do?
  2. Is O304 the same compound as ATX-304?
  3. How does O304 activate AMPK?
  4. What did the mouse studies find?
  5. The heart-weight question
  6. The phase IIa trial in type 2 diabetes: target engagement or clinical outcome?
  7. Regulatory status, and where it sits beside the compounds in this catalogue
  8. Frequently asked questions

ATX-304 is an investigational small molecule, first published as O304 by the Swedish company Betagenon, that activates AMP-activated protein kinase (AMPK), the cell's main energy sensor. It is a pan-AMPK activator, acting on all forms of the enzyme. Most of the evidence comes from mice, where it was examined in diabetes, ageing, heart, kidney and fatty-liver models. In people, the only published data come from a small proof-of-concept phase IIa trial in type 2 diabetes. Later work found it is also a mitochondrial uncoupler. It is not approved anywhere.

A mitochondrion beside a protein enzyme complex, in the style of a micrograph
Illustration in the style of a micrograph, not experimental data: mitochondria and an energy-sensing enzyme.

What does AMPK do?

AMPK is a kinase that reads the cell's energy charge. When ATP falls and AMP and ADP rise, AMPK is activated. It then switches on processes that make ATP, such as glucose uptake and fatty-acid oxidation, and switches off processes that spend it, such as fat, cholesterol and protein synthesis. Beyond single cells, it also regulates whole-body energy balance, including feeding signals in the hypothalamus (PMID 22436748). Exercise and caloric restriction both activate it, which is why AMPK activators are so often called "exercise mimetics". The same label is applied to the estrogen-related receptor agonists in our SLU-PP-332 vs SLU-PP-915 comparison.

The enzyme has three subunits, each in more than one form, so mammals have twelve distinct AMPK complexes spread unevenly across tissues. A "pan" activator hits all twelve. That breadth is what makes such compounds interesting, and also what makes them hard to develop. AMPK sits in almost every tissue, so switching it on everywhere means effects everywhere, including places nobody intended.

Many molecules affect AMPK indirectly. Metformin does, the mitochondrial peptide MOTS-c is reported to, and changes in NAD+ status can too (NAD+ and the mitochondrion). Showing AMPK activation in a tissue sample is therefore easy. Showing that AMPK activation caused the outcome is not, and that distinction runs through everything below.

Is O304 the same compound as ATX-304?

The papers point that way, though none of the abstracts states it outright. O304 was developed by Betagenon. From 2024 the literature uses the name ATX-304 instead, and a 2024 kidney study discloses that "Amplifier Therapeutics (Betagenon)" supplied the ATX-304 it tested (PMID 38749175). A 2025 fatty-liver paper on ATX-304 comes from the same Swedish group that published the earlier O304 islet work. Amplifier Therapeutics, a Cambrian Bio pipeline company, has publicly described acquiring the compound from Betagenon. This article treats the two names as one molecule at different stages of development, and cites each paper under the name it used.

How does O304 activate AMPK?

AMPK is switched on when a specific threonine on its catalytic subunit is phosphorylated and switched off when phosphatases remove that phosphate. O304 is reported to work on the second step. It was identified as a pan-AMPK activator that acts by inhibiting protein phosphatase 2C, keeping the enzyme active rather than directly forcing it on (PMID 41130350).

The more surprising finding came later. In 2023 Betagenon-affiliated authors reported that O304 also acts as a mitochondrial uncoupler: it lets protons leak back across the inner mitochondrial membrane without making ATP. That burns fuel, creates the metabolic demand that glucose uptake needs, and lowers cellular energy charge, which itself activates AMPK (PMID 37626210). A separate group with no declared competing interests confirmed the uncoupling in vascular smooth muscle and liver cell lines in 2025. They reported that O304 lowered mitochondrial membrane potential, extended lifespan in the nematode C. elegans through an AMPK–mTOR pathway, and relaxed rat mesenteric arteries independently of the endothelium (PMID 41130350).

This matters for interpreting every result. If a compound is an uncoupler, some of what is credited to "AMPK activation" may be the uncoupling, with AMPK activation as one consequence of it. Mild uncoupling is also a pharmacology with a known history of narrow margins, so the dual mechanism is a reason for more safety work, not less.

What did the mouse studies find?

PaperModelReported findings
Steneberg 2018Diet-induced obese mice; ratsHigher muscle glucose uptake, less β-cell stress; cardiac AMPK activation and glucose uptake with lower cardiac glycogen; better stroke volume; no increase in heart weight
Ericsson 2021Aged micePrevented and reversed age-associated hyperinsulinaemia and insulin resistance; better cardiac function and exercise capacity
López-Pérez 2021High-fat-fed mice, pancreatic isletsLargely prevented diet-induced gene-expression and chromatin changes in islets, including the β-cell stress marker Aldh1a3
Norlin 2023Diabetic mice, including db/dbInsulin-independent glucose uptake in muscle and heart; uncoupling identified; β-cell function preserved; reversal of diabetic cardiomyopathy
Katerelos 2024 (as ATX-304)Cisplatin kidney injury in mice; kidney cellsLess injury by creatinine, NGAL and histology; protection lost in AMPK-null cells
Holm 2025 (as ATX-304)Progressive fatty-liver model in miceLower fat mass and cholesterol; less steatosis and fibrosis, with marked differences between liver regions

Sources: PMID 29925691, 34795407, 34949756, 37626210, 38749175, 40197369.

Two things stand out. First, the kidney study did a dependency test: the protective effect disappeared in cells lacking AMPK (PMID 38749175). That kind of experiment links an outcome to the target, and it is rare in this literature. Second, nearly all the metabolic and cardiac work comes from the developer's founders and collaborators, with conflicts disclosed in each paper. The kidney study was independent in design and funding, though it used compound supplied by the developer. The fatty-liver paper reported "pronounced local heterogeneities" across the liver rather than a uniform effect (PMID 40197369).

The heart-weight question

The heart deserves its own section because it is where pan-AMPK activators have failed before. MK-8722, a direct allosteric activator of all twelve AMPK complexes, improved blood glucose in rodents and diabetic rhesus monkeys. Across species, those effects came with cardiac hypertrophy and raised cardiac glycogen, though without apparent functional consequences (PMID 28705990). AMPK activation in heart muscle drives glucose uptake and glycogen storage, and a heavier heart was the result.

The O304 papers report the opposite pattern in the heart: lower cardiac glycogen and no increase in heart weight in mice or rats (PMID 29925691). The uncoupling finding offers a plausible explanation. If O304 also creates energy demand, the glucose it pulls into the heart is burned rather than stored. But this is a comparison across different laboratories, species panels and study lengths. It is a hypothesis about why the two compounds differ, not a demonstration that ATX-304 is free of the problem. Long-term cardiac safety in humans is exactly what has not yet been measured.

The phase IIa trial in type 2 diabetes: target engagement or clinical outcome?

The one published human study appears inside the 2018 JCI Insight paper. It describes a proof-of-concept phase IIa trial in people with type 2 diabetes who were already taking metformin. O304 lowered fasting plasma glucose and HOMA-IR, an index of insulin resistance. The paper also reports better peripheral microvascular perfusion and lower blood pressure, in both animals and patients (PMID 29925691). The 2021 ageing paper describes the compound as well tolerated in humans (PMID 34795407).

Read carefully, that is a short, early signal on surrogate markers. Fasting glucose, insulin-resistance indices, perfusion and blood pressure are reasonable things to measure in a proof-of-concept study, but none of them is an outcome. HbA1c durability, cardiovascular events, kidney function and long-term safety have not been reported. The trial's full size, duration and design are in the paper rather than the abstract, and should be read there before quoting any effect. A phase IIa study in people already on metformin tests whether the drug does anything on top of standard care. It cannot test whether it does something worth having over years. The distinction is set out in how to read a peptide study.

Amplifier Therapeutics announced a phase 1b study in Europe in 2023, in overweight people with prediabetes, focused on safety and pharmacokinetics. We could not find it registered on ClinicalTrials.gov, and we found no published results.

Regulatory status, and where it sits beside the compounds in this catalogue

ATX-304 is not approved by any regulator, including Health Canada, the US Food and Drug Administration or the European Medicines Agency. It is not sold in this catalogue. Like 5-amino-1MQ, it is a small molecule, not a peptide, despite turning up in peptide catalogues. The comparison of NNMT inhibition and AMPK activation in our 5-amino-1MQ muscle research article explains why the two are often mentioned together and why they are different mechanisms. For AMPK-adjacent research material that is in the catalogue, MOTS-c is the closest. It is a different molecule with its own, still thin, literature. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is ATX-304 a peptide? No. ATX-304, published earlier as O304, is a synthetic small molecule. It shows up in peptide catalogues because it is sold through the same research-chemical channels, but its chemistry, synthesis and analysis are those of a small-molecule drug candidate, and a peptide certificate format may not fit it.

Has ATX-304 been tested in humans? In one small way. A proof-of-concept phase IIa trial in people with type 2 diabetes on metformin is reported in the 2018 paper, with lower fasting glucose and insulin-resistance index. The developer later announced a phase 1b safety study. No larger trial, outcome trial or regulatory approval exists.

What is the difference between a direct and an indirect AMPK activator? A direct activator binds the AMPK enzyme itself, as MK-8722 does. An indirect one changes the cell's energy state, or the enzymes that switch AMPK off, so that AMPK becomes more active. O304 is reported to do both indirect things: it inhibits a phosphatase and uncouples mitochondria.

Why does the mitochondrial uncoupler finding matter? Because it changes what the results mean. Effects attributed to AMPK activation may partly come from uncoupling, which burns fuel without making ATP. Uncoupling also has a history of narrow safety margins, so it raises the bar for the long-term human safety data that do not yet exist.

Does activating AMPK slow ageing? Not in any way shown in humans. O304 extended lifespan in nematodes and improved several measures in aged mice. AMPK is one of several energy-sensing pathways studied in ageing biology, but no AMPK activator has been shown to change human ageing, and worm lifespan results often fail to translate to mammals.

Selected Research References

  1. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262. pubmed.ncbi.nlm.nih.gov/22436748
  2. Steneberg P, Lindahl E, Dahl U, et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018;3(12):e99114. pubmed.ncbi.nlm.nih.gov/29925691
  3. Myers RW, Guan HP, Ehrhart J, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science. 2017;357(6350):507-511. pubmed.ncbi.nlm.nih.gov/28705990
  4. Ericsson M, Steneberg P, Nyrén R, Edlund H. AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice. Commun Biol. 2021;4(1):1306. pubmed.ncbi.nlm.nih.gov/34795407
  5. López-Pérez A, Norlin S, Steneberg P, et al. Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice. Sci Rep. 2021;11(1):24410. pubmed.ncbi.nlm.nih.gov/34949756
  6. Norlin S, Axelsson J, Ericsson M, Edlund H. O304 ameliorates hyperglycemia in mice by dually promoting muscle glucose effectiveness and preserving β-cell function. Commun Biol. 2023;6(1):877. pubmed.ncbi.nlm.nih.gov/37626210
  7. Katerelos M, Gleich K, Harley G, et al. The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury. Biomed Pharmacother. 2024;175:116730. pubmed.ncbi.nlm.nih.gov/38749175
  8. Holm E, Vermeulen I, Parween S, et al. AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight. 2025;10(7):e179990. pubmed.ncbi.nlm.nih.gov/40197369
  9. Li WF, Zeng Y, Zhang YD, et al. O304 is a mitochondrial uncoupler which extends C. elegans lifespan and induces vasorelaxation of rat mesenteric arteries. Chem Biol Interact. 2025;421:111788. pubmed.ncbi.nlm.nih.gov/41130350

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.